Anthony Yu
Anthony Yu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ilya Okunev
Inovalon, Inc
2 shared publications - Joseph Christopher Cappelleri
Pfizer Inc. New York New York USA
2 shared publications - Karen L. Rascati
Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA
2 shared publications - Paul Godley
Baylor Scott & White Health, Temple, TX, USA
2 shared publications - Alexander Russell-Smith
Pfizer, R&D UK Ltd
1 shared publication - Alexandra Ritenour
CHRISTUS Health Irving Texas USA
1 shared publication
Latest Publications
- 3 February 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (3) , 582-591
Healthcare resource utilization, costs, and survival among Medicare beneficiaries with relapsed or refractory DLBCL receiving second-line therapy: a real-world evidence study
Chemotherapy is the main treatment for diffuse large B-cell lymphoma (DLBCL); yet 30-40% of patients are considered relapsed or refractory (R/R) to initial therapy and have second-line therapy (2 L). There is a need to study real-world outcomes to address the changing treatment landscape for R/R DLBCL patients. This study examined treatment patterns, healthcare utilization and costs, and survival among Medicare R/R DLBCL patients from 2016 to 2022. Study patients (n = 3,191) were an average of 75.7 years old and only 30.6% of patients initiated 3 L. Patients with 3 L incurred higher costs ($15,133 per-patient per-month [PPPM]) than all patients ($9,487 PPPM). Half of patients died within 6.7 months from start of 2 L. Patients with older age and elevated comorbidity burden had significantly shorter survival times within 3 years after 2 L initiation. Our analyses indicate a high disease burden among R/R DLBCL patients, highlighting the need for new treatments.
- 3 February 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (3) , 582-591
Healthcare resource utilization, costs, and survival among Medicare beneficiaries with relapsed or refractory DLBCL receiving second-line therapy: a real-world evidence study
Chemotherapy is the main treatment for diffuse large B-cell lymphoma (DLBCL); yet 30-40% of patients are considered relapsed or refractory (R/R) to initial therapy and have second-line therapy (2 L). There is a need to study real-world outcomes to address the changing treatment landscape for R/R DLBCL patients. This study examined treatment patterns, healthcare utilization and costs, and survival among Medicare R/R DLBCL patients from 2016 to 2022. Study patients (n = 3,191) were an average of 75.7 years old and only 30.6% of patients initiated 3 L. Patients with 3 L incurred higher costs ($15,133 per-patient per-month [PPPM]) than all patients ($9,487 PPPM). Half of patients died within 6.7 months from start of 2 L. Patients with older age and elevated comorbidity burden had significantly shorter survival times within 3 years after 2 L initiation. Our analyses indicate a high disease burden among R/R DLBCL patients, highlighting the need for new treatments.
- Open Access
- 3 December 2025
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (29) , 3811-3820
Real-world treatment and utilization of venetoclax for incident acute myeloid leukemia in a Medicare population
This study aimed to describe first-line venetoclax in the Medicare population and its impacts on treatment patterns, utilization, and costs. This retrospective cohort study used Medicare Fee-For-Service data from 1 September 2016, to 31 December 2022. Patients were continuously-enrolled, had incident acute myeloid leukemia (AML) and no confounding diagnoses, and were treated with first-line venetoclax-based regimens. Initiation of second line of therapy was modeled using cumulative incidence functions. Among 2,765 included patients, median age was 76 years. Median venetoclax dosage was 140.4 mg/day - lower than the 400-600 mg/day recommended by clinical guidelines. Patients were less likely to initiate second-line therapy if they were older or had more comorbidities.Patients had a per-month median of 5.3 outpatient visits, 0.3 emergency department visits, and 0.2 hospitalizations; length of stay was 10 days. Mean monthly healthcare costs were $18,092 (SD=$14,289) per patient, with $12,042 (SD=$12,147) and $6,050 (SD=$7,841) attributable to medical services and drug costs, respectively. A growing number of patients enrolled in Medicare Fee-For-Service with AML use first-line venetoclax. Older patients and those with comorbidities are less likely to initiate second-line therapy. Costs were lower and length of stay was shorter than described in previous research.
- 3 December 2025
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (29) , 3811-3820
Open AccessReal-world treatment and utilization of venetoclax for incident acute myeloid leukemia in a Medicare population
This study aimed to describe first-line venetoclax in the Medicare population and its impacts on treatment patterns, utilization, and costs. This retrospective cohort study used Medicare Fee-For-Service data from 1 September 2016, to 31 December 2022. Patients were continuously-enrolled, had incident acute myeloid leukemia (AML) and no confounding diagnoses, and were treated with first-line venetoclax-based regimens. Initiation of second line of therapy was modeled using cumulative incidence functions. Among 2,765 included patients, median age was 76 years. Median venetoclax dosage was 140.4 mg/day - lower than the 400-600 mg/day recommended by clinical guidelines. Patients were less likely to initiate second-line therapy if they were older or had more comorbidities.Patients had a per-month median of 5.3 outpatient visits, 0.3 emergency department visits, and 0.2 hospitalizations; length of stay was 10 days. Mean monthly healthcare costs were $18,092 (SD=$14,289) per patient, with $12,042 (SD=$12,147) and $6,050 (SD=$7,841) attributable to medical services and drug costs, respectively. A growing number of patients enrolled in Medicare Fee-For-Service with AML use first-line venetoclax. Older patients and those with comorbidities are less likely to initiate second-line therapy. Costs were lower and length of stay was shorter than described in previous research.
- 21 February 2024
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 44 (3) , 209-217
Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model
Background and Objectives Two oral calcitonin gene-related peptide (CGRP) antagonists, atogepant and rimegepant, were approved in 2021 for the preventive treatment of episodic migraine (EM), yet no formal cost-effectiveness analysis has been published. The objective of this study was to evaluate the cost-effectiveness of atogepant 60 mg and rimegepant 75 mg compared with placebo. Methods A decision tree model was constructed over a 1-year time horizon from a US societal perspective. Patient cohorts were simulated using baseline and change from baseline monthly migraine days (MMDs) reported in the trials to incorporate responder rates and within patient response into the model. Due to heterogeneity between the trial populations, each medication was compared with its respective trial’s placebo group. Direct healthcare resource costs, productivity costs, acute medication costs, and quality-of-life values were obtained from the literature. Results The atogepant cohort experienced an incremental increase in healthcare plus productivity costs of $11,978 when compared with placebo, with a gain of 0.026 quality-adjusted life-years (QALYs). This yielded an incremental cost-effectiveness ratio (ICER) of more than $450,000/QALY. The rimegepant cohort experienced an incremental increase of $21,692 when compared with placebo, with a gain of 0.024 QALYs. This yields an ICER of more than $890,000/QALY when comparing rimegepant with placebo. Cost savings between atogepant and atogepant placebo were greatest with respect to acute medication costs at $735 of savings over 1 year, followed by savings of $135 for healthcare resource utilization and $34 for productivity costs. A similar relationship was seen between rimegepant and rimegepant placebo. One-way deterministic sensitivity analysis found that monthly acquisition costs of atogepant and rimegepant had the largest impact on the ICER, respectively. Conclusions Atogepant and rimegepant were both unable to meet generally accepted cost-effectiveness thresholds < 150,0000/QALY. Additional studies are needed to better guide decision making regarding oral CGRPs’ place in therapy.
- 21 February 2024
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 44 (3) , 209-217
Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model
Background and Objectives Two oral calcitonin gene-related peptide (CGRP) antagonists, atogepant and rimegepant, were approved in 2021 for the preventive treatment of episodic migraine (EM), yet no formal cost-effectiveness analysis has been published. The objective of this study was to evaluate the cost-effectiveness of atogepant 60 mg and rimegepant 75 mg compared with placebo. Methods A decision tree model was constructed over a 1-year time horizon from a US societal perspective. Patient cohorts were simulated using baseline and change from baseline monthly migraine days (MMDs) reported in the trials to incorporate responder rates and within patient response into the model. Due to heterogeneity between the trial populations, each medication was compared with its respective trial’s placebo group. Direct healthcare resource costs, productivity costs, acute medication costs, and quality-of-life values were obtained from the literature. Results The atogepant cohort experienced an incremental increase in healthcare plus productivity costs of $11,978 when compared with placebo, with a gain of 0.026 quality-adjusted life-years (QALYs). This yielded an incremental cost-effectiveness ratio (ICER) of more than $450,000/QALY. The rimegepant cohort experienced an incremental increase of $21,692 when compared with placebo, with a gain of 0.024 QALYs. This yields an ICER of more than $890,000/QALY when comparing rimegepant with placebo. Cost savings between atogepant and atogepant placebo were greatest with respect to acute medication costs at $735 of savings over 1 year, followed by savings of $135 for healthcare resource utilization and $34 for productivity costs. A similar relationship was seen between rimegepant and rimegepant placebo. One-way deterministic sensitivity analysis found that monthly acquisition costs of atogepant and rimegepant had the largest impact on the ICER, respectively. Conclusions Atogepant and rimegepant were both unable to meet generally accepted cost-effectiveness thresholds < 150,0000/QALY. Additional studies are needed to better guide decision making regarding oral CGRPs’ place in therapy.
- 30 November 2023
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 136 (1) , 14-21
Exploring factors related to clinically advanced fibrosis in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis
To describe the clinical profile of nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) patients in a Texas integrated delivery network (IDN) and elucidate the local relationship between patient factors and the risk of advanced fibrosis. This observational, retrospective, cross-sectional study utilized existing data from the electronic health record at a large Texas IDN. Data was collected during the study period from 1 January 2019, to 1 March 2023. Patient characteristics, comorbidities, labs, and medication orders were collected from the most recent encounter in which a Fibrosis-4 (FIB-4) score could be calculated. Chi square tests and analysis of variance (ANOVA) tests were conducted to evaluate differences among the three fibrosis risk categories. Ordinal logistic regression was utilized to assess associations between select variables and a higher risk of advanced fibrosis. A total of 56,253 patients were included in the study. 34,839 (61.9%) were Low-Risk 15,578 (27.7%) were Intermediate-Risk, and 5,836 (10.4%) were High-Risk of advanced fibrosis. Results showed that up to 70.4% of patients within a risk group were obese. Only 49.5% of patients in the High-Risk group had at least one gastroenterologist or hepatologist visit. Males, Medicare patients, former smokers, and those with hypertension, type 2 diabetes, and chronic kidney disease were associated with a higher risk of advanced fibrosis. This study highlights the need for early screening and proactive management of metabolic risk factors for patients with NAFLD/NASH. The findings indicate a notable prevalence of obesity in the study population, a need for specialist referral for those at High-Risk of advanced fibrosis, and the importance of routine labs to evaluate metabolic factors. Primary care providers may be ideal providers to target these interventions and address this care need.
- 30 November 2023
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 136 (1) , 14-21
Exploring factors related to clinically advanced fibrosis in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis
To describe the clinical profile of nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) patients in a Texas integrated delivery network (IDN) and elucidate the local relationship between patient factors and the risk of advanced fibrosis. This observational, retrospective, cross-sectional study utilized existing data from the electronic health record at a large Texas IDN. Data was collected during the study period from 1 January 2019, to 1 March 2023. Patient characteristics, comorbidities, labs, and medication orders were collected from the most recent encounter in which a Fibrosis-4 (FIB-4) score could be calculated. Chi square tests and analysis of variance (ANOVA) tests were conducted to evaluate differences among the three fibrosis risk categories. Ordinal logistic regression was utilized to assess associations between select variables and a higher risk of advanced fibrosis. A total of 56,253 patients were included in the study. 34,839 (61.9%) were Low-Risk 15,578 (27.7%) were Intermediate-Risk, and 5,836 (10.4%) were High-Risk of advanced fibrosis. Results showed that up to 70.4% of patients within a risk group were obese. Only 49.5% of patients in the High-Risk group had at least one gastroenterologist or hepatologist visit. Males, Medicare patients, former smokers, and those with hypertension, type 2 diabetes, and chronic kidney disease were associated with a higher risk of advanced fibrosis. This study highlights the need for early screening and proactive management of metabolic risk factors for patients with NAFLD/NASH. The findings indicate a notable prevalence of obesity in the study population, a need for specialist referral for those at High-Risk of advanced fibrosis, and the importance of routine labs to evaluate metabolic factors. Primary care providers may be ideal providers to target these interventions and address this care need.
- 10 June 2023
- Published by Elsevier in Value in Health
- Vol. 26 (6) , S42
CO145 Comparison of Clinical Outcomes and Healthcare Utilization with Newer Diabetes Medications in Patients with Type 2 Diabetes
- 10 June 2023
- Published by Elsevier in Value in Health
- Vol. 26 (6) , S42
CO145 Comparison of Clinical Outcomes and Healthcare Utilization with Newer Diabetes Medications in Patients with Type 2 Diabetes